{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-194655","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2023-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.743534+00:00","generated_at":"2026-06-13T02:22:30.922716+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"Amylyx announces conference call on AMX0035 Phase 3 PSP trial; no new data","bullets":["Hosted investor call on July 26, 2023 to discuss PSP and Orion Phase 3 trial of AMX0035.","No clinical results or data disclosed; only trial design and scientific rationale overview.","Presenters included co-CEOs, clinical development head, and external investigator Prof. Höglinger.","Attached slides outline rationale and design, not outcomes or milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-194655","json":"https://secwatch.observer/filing/0001193125-23-194655.json","markdown":"https://secwatch.observer/filing/0001193125-23-194655.md","text":"https://secwatch.observer/filing/0001193125-23-194655.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000119312523194655/0001193125-23-194655-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000119312523194655/d498667d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T02:22:30.922716+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}